ERNA Ernexa Therapeutics Inc.
Listings ·
Nasdaq staff says Ernexa's stock failed to maintain a $1.00 minimum bid price for 30 consecutive business days, and that the company is not eligible for a 180-calendar day compliance period because of a reverse stock split in the past year. The company plans to request a hearing.
Eterna Therapeutics (now Ernexa Therapeutics, Nasdaq: ERNA) received $1,500,000 on March 11, 2025, under a promissory note with 5.0% interest that matures no later than June 15, 2025.
Stockholders approved the share issuances at the annual meeting on October 29, 2024, the same day the placement closed. The company also agreed to register the new shares for resale, and its equity had been below Nasdaq's $2.5 million minimum.
Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are mesenchymal stem cells derived from induced pluripotent stem cells. Its lead product candidate, ERNA-101, is an allogeneic iMSC therapy that secretes IL-7 and IL-15, with an initial focus on platinum-resistant ovarian cancer. In a preclinical study with the University of Texas MD Anderson Cancer Center, ERNA-101 reduced tumor growth and showed a statistically significant survival advantage compared with the control group in an ovarian cancer model. After a successful pre-IND meeting with the FDA in the fourth quarter of 2025, the company expects to complete IND-enabling studies and submit an IND in 2026, and to enter a Phase I investigator sponsored trial in the second half of 2026. The company is also investigating ERNA-201, an IL-10 secreting iMSC, in autoimmune disorders such as rheumatoid arthritis. Its technology is in-licensed from Factor Bioscience Limited under an exclusive license in the fields of cancer, autoimmune disorders and rare diseases. The company is seeking strategic partnerships and research grants.
| Product or program | What it is | Stage |
|---|---|---|
| ERNA-101 | Allogeneic IL-7 and IL-15-secreting iMSCs for platinum-resistant ovarian cancer | Preclinical; IND submission expected in 2026 |
| ERNA-201 | IL-10-secreting iMSCs for autoimmune disorders such as rheumatoid arthritis | Under investigation |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $582,000 | |
| Net income (loss) | -$14.1 million | -$44.5 million |
| Cash from operations | -$7.0 million | -$15.8 million |
| Cash and equivalents | $1.9 million | $1.7 million |
Our latest story on this, dated Mar 20, 2026: "Ernexa Therapeutics gets Nasdaq minimum bid price notice, plans to request hearing". The story links the filing or release it is based on. Read the story.
Ernexa Therapeutics Inc. trades under the ticker ERNA on NASDAQ.
Ernexa Therapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Ernexa Therapeutics Inc. is 748592. Its filings are on SEC EDGAR.
1,632,411 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Ernexa Therapeutics Inc. under United States.
Our directory classifies Ernexa Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Ernexa Therapeutics Inc. is US1140824079.
aibio.space lists Ernexa Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are mesenchymal stem cells derived from induced pluripotent stem cells. Its lead product candidate, ERNA-101, is an allogeneic iMSC therapy that secretes IL-7 and IL-15, with an initial focus on platinum-resistant ovarian cancer.
ERNA-101: Allogeneic IL-7 and IL-15-secreting iMSCs for platinum-resistant ovarian cancer Stage: Preclinical; IND submission expected in 2026.
ERNA-201: IL-10-secreting iMSCs for autoimmune disorders such as rheumatoid arthritis Stage: Under investigation.
Ernexa Therapeutics Inc. reported a net loss of $14.1 million for the fiscal year ended Dec 31, 2025, and used $7.0 million of cash in operations, per its annual report to the SEC.
$5.0 million in cash at Jun 30, 2026, per its 10-Q.
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form S-1. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio